Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Christy Chuang"'
Autor:
Simon Kirby, Christy Chuang‐Stein
Publikováno v:
Pharmaceutical Statistics. 21:720-728
The Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN) study, initiated in November of the year 2000, is now widely recognized as having been a landmark study in the history of clinical trials. We look at why this is the case by considering it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09595f6a276b7a521599705cec75bb02
https://doi.org/10.1002/pst.2218
https://doi.org/10.1002/pst.2218
Autor:
Christy Chuang-Stein, Simon Kirby
Publikováno v:
Statistics in Biopharmaceutical Research. 13:36-39
We want to congratulate Gibson on a well-articulated and illuminating article. Gibson (2020) addressed the so-called replication crisis in scientific research and argued that the crisis was to a la...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78af0b7563524db4b51d800e4516e7d4
https://doi.org/10.1080/19466315.2020.1807404
https://doi.org/10.1080/19466315.2020.1807404
Autor:
Christy Chuang-Stein, Simon Kirby
Publikováno v:
Quantitative Decisions in Drug Development ISBN: 9783030797300
Quantitative Decisions in Drug Development ISBN: 9783319460758
Quantitative Decisions in Drug Development ISBN: 9783319460758
In this chapter, we compare successive trials designed and conducted to assess the efficacy of a new drug to a series of diagnostic tests. The condition to diagnose is whether the new drug has a clinically meaningful efficacious effect. This comparis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d94644782eeb215c29a764af6ff02aa4
https://doi.org/10.1007/978-3-030-79731-7_4
https://doi.org/10.1007/978-3-030-79731-7_4
Autor:
Simon Kirby, Christy Chuang-Stein
Publikováno v:
Quantitative Decisions in Drug Development ISBN: 9783030797300
Quantitative Decisions in Drug Development ISBN: 9783319460758
Quantitative Decisions in Drug Development ISBN: 9783319460758
Phase 4 trials are conducted for a variety of reasons. These include investigating a marketed drug in pediatric patients, comparing a drug head-to-head with another drug, investigating the effect of a drug at a lower/higher dose or with different adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae839937f081f9476595d34191e0544c
https://doi.org/10.1007/978-3-030-79731-7_10
https://doi.org/10.1007/978-3-030-79731-7_10
Autor:
Christy Chuang-Stein, Simon Kirby
Publikováno v:
Quantitative Decisions in Drug Development ISBN: 9783030797300
Drug development is a continuum. Information from completed trials and other sources may be available when we design a new trial. In this chapter, we consider the Bayesian approach to incorporate existing information into future trial planning. Under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d35533526b098cea084879cf5a07e0d1
https://doi.org/10.1007/978-3-030-79731-7_5
https://doi.org/10.1007/978-3-030-79731-7_5
Autor:
Christy Chuang-Stein, Simon Kirby
Publikováno v:
Quantitative Decisions in Drug Development ISBN: 9783030797300
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5674a876d5004c5cb7425cba531b61dc
https://doi.org/10.1007/978-3-030-79731-7_13
https://doi.org/10.1007/978-3-030-79731-7_13
Autor:
Christy Chuang-Stein, Simon Kirby
Publikováno v:
Quantitative Decisions in Drug Development ISBN: 9783030797300
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c92296370725bc88baba7a2081f86369
https://doi.org/10.1007/978-3-030-79731-7_8
https://doi.org/10.1007/978-3-030-79731-7_8
Autor:
Christy Chuang-Stein, Simon Kirby
Publikováno v:
Quantitative Decisions in Drug Development ISBN: 9783030797300
Quantitative Decisions in Drug Development ISBN: 9783319460758
Quantitative Decisions in Drug Development ISBN: 9783319460758
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1fc6f1725afb9ae6f58cee36e464661
https://doi.org/10.1007/978-3-030-79731-7_14
https://doi.org/10.1007/978-3-030-79731-7_14
Autor:
Haijun Ma, Soomin Park, Cyrus R. Mehta, Richard C. Zink, Jeff Maca, Chunlei Ke, Qi Jiang, Christy Chuang-Stein, Matilde Sanchez-Kam, Olga Marchenko, Estelle Russek-Cohen, Mark Levenson, Lingyun Liu
Publikováno v:
Statistics in Biopharmaceutical Research. 9:347-360
This is the second article written by the American Statistical Association Biopharmaceutical Section Safety Working Group. In the first article, we reviewed the drugs approved by the United States Food and Drug Administration to treat type 2 diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b320080bd714c1ff9a578e69e30cb1cf
https://doi.org/10.1080/19466315.2017.1280411
https://doi.org/10.1080/19466315.2017.1280411
Autor:
Jianjun David Li, Christy Chuang-Stein
Publikováno v:
Statistics in Medicine. 36:4427-4436
The Food and Drug Administration in the United States issued a much-awaited draft guidance on 'Multiple Endpoints in Clinical Trials' in January 2017. The draft guidance is well written and contains consistent message on the technical implementation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ea2c4001f57bb45608694db6eabc829
https://doi.org/10.1002/sim.7383
https://doi.org/10.1002/sim.7383